{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"The proportion of patients who have at least a confirmed very good partial response will be calculated by taking the number of patients with a very good partial response or a complete response divided by the total number of patients.\n\nA complete response is defined as:\n\n* Negative immunofixation of the serum and urine\n* If at on study, only the measurable non-bone marrow parameter was FLC, normalization of FLC ratio\n* \\< 5% plasma cells in bone marrow\n* Disappearance of any soft tissue plasmacytomas\n\nA very good partial response is defined as:\n\n* Serum and urine M-component detectable by immunofixation but not on electrophoresis or\n* If at on study, serum measurable, ≥ 90% or greater reduction in serum Mcomponent\n* Urine M-component \\<100 mg per 24 hour","groups":[{"description":"Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","populationDescription":"All enrolled patients who began treatment were evaluated for safety and response.","reportingStatus":"POSTED","timeFrame":"Following the first 4 cycles of treatment (28 day cycles)","title":"Percentage of Patients Who Have at Least a Confirmed Very Good Partial Response (Phase II)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}